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Abstract
The Escherichia coli ChrR enzyme is an obligatory two-electron quinone reductase that has many applications, such as in
chromate bioremediation. Its crystal structure, solved at 2.2 A ˚ resolution, shows that it belongs to the flavodoxin
superfamily in which flavin mononucleotide (FMN) is firmly anchored to the protein. ChrR crystallized as a tetramer, and size
exclusion chromatography showed that this is the oligomeric form that catalyzes chromate reduction. Within the tetramer,
the dimers interact by a pair of two hydrogen bond networks, each involving Tyr128 and Glu146 of one dimer and Arg125
and Tyr85 of the other; the latter extends to one of the redox FMN cofactors. Changes in each of these amino acids
enhanced chromate reductase activity of the enzyme, showing that this network is centrally involved in chromate reduction.
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Introduction
Chromate [Cr(VI)] and other soluble forms of heavy metals and
radionuclides are serious environmental pollutants in many
hazardous environments, including the U.S. Department of
Energy waste sites and corresponding facilities worldwide [1].
The use of Shewanella and Geobacter bacteria has been intensely
studied as a potential cost effective solution to this problem. These
bacteria can convert the soluble form of many such contaminants,
e.g., Cr(VI) and uranyl [U(VI)], to their insoluble valence state of
Cr(III) and U(IV), thus making it possible to prevent their spread.
While unique features of the membrane-bound electron transport
chain enable these bacteria to mediate the dissimilatory reductions
[2,3], we showed that nearly all bacteria possess an additional
means of chromate reduction, involving soluble enzymes [4,5,6].
However, the effectiveness of bacteria utilizing either mechanism
to reduce chromate is hampered because of its toxicity [4,5,7,8].
The latter arises mainly due to the fact that many bacterial
metabolic enzymes, e.g., glutathione reductase and lipoyl dehy-
drogenase, can vicariously reduce chromate and do so by one
electron reduction [4,5,8]. This generates the highly reactive Cr(V)
radical, which redox cycles. In this process, Cr(V) is oxidized back
to Cr(VI), giving its electron to dioxygen and generating reactive
oxygen species (ROS). Repetition of this process results in the
generation of large quantities of ROS, which poison the cells due
to oxidative stress and exhaustion of the cell’s reducing power
(NAD[P]H) [4,9].
Conversion of Cr(VI) to Cr(III) involves the transfer of three
electrons, and if it could be brought about in one step, it would
obviate Cr(V) generation. We discovered the soluble ChrR class of
enzymes in search for such a mechanism. This class of enzymes is
widely distributed in bacteria [6,10], and can greatly mitigate
redox cycling not only by a one-step reduction of chromate to
Cr(III) but also by preempting its reduction by cellular one-
electron reducers [4,5]. We have also shown that the Escherichia coli
ChrR enzyme can bring about ‘safe’ reduction of uranyl as well
(by avoiding redox cycling) to its insoluble valence state of U(IV)
[7]. Overproduction of ChrR in wild type E. coli cells markedly
augmented their capacity to remediate chromate and uranyl [7]
and since dissimilatory bacteria are also poisoned by heavy metals,
the protective effect of such overproduction is likely to apply to
them as well [4,5,9]. Reduction of metals/radionuclides by cellular
soluble enzymes has the advantage that unlike the dissimilatory
reduction, the reduced species is not directly released into the
environment, where it might be subjected to re-oxidation [6].
Moreover, dissimilatory reduction is inhibited by nitrate and
oxygen, which are commonly present in polluted environments;
this is not the case with reductions mediated by the soluble
enzymes [4,7,10,11]. Another valuable feature of ChrR is that it
can activate several cancer prodrugs and has proven useful in
cancer chemotherapy, such as by our recently discovered prodrug
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[12,13].
The physiological role of the E. coli ChrR is quinone reductase,
and this is likely to be the case for enzymes of this class also in
other bacteria [14]. Reductions mediated by ChrR involve
electron transfer from NADH to the various substrates via ping-
pong bi-bi (double displacement) reaction resulting in the transfer
of electrons from NADH to the enzyme bound flavin co-factor,
which subsequently passes them on to the enzyme substrate [10].
No reactive radicals [like Cr(V), U(V), Q
N etc.] are thus generated,
and redox cycling and ROS generation are eliminated or greatly
minimized during reduction of diverse electrophiles [4,5,14].
In order to gain mechanistic insights into this important
enzyme, which could afford rational means for its improvement,
we report here the crystal structure of the E. coli ChrR enzyme at
2.2 A ˚ resolution. The enzyme crystallizes as a tetramer, which is
also its active oligomeric form. We also show that a hydrogen bond
network involving four amino acids at the dimer-dimer interface
and reaching towards the flavin mononucleotide (FMN) cofactor
plays a central role in chromate reductase activity of ChrR.
Materials and Methods
Escherichia coli BL21 (DE3) was cultivated in Luria-Bertani (LB)
broth supplemented with kanamycin (30 mg/mL), or ampicillin
(50 mg/mL). ChrR was generated and purified as described
previously [4,5,9]. E. coli BL21 (DE3) and plasmid pET28a or
pTYB3 (New England BioLabs, Ipwsich, MA) were used to
generate histidine- or intein-tagged proteins, respectively. Protein
expression was induced with isopropyl-ß-D-thiogalactopyranoside
(IPTG, 0.1 mM) at 20uC for 20 h. The proteins were purified
using His-Trap nickel, or chitin bead columns and the tags were
removed either by thrombin cleavage kit (Novagen) or DTT
treatment (IMPACT protein purification kit, New England
BioLabs). Gelfiltration was performed for further purification of
the proteins using a 26/600 Superdex 200 column (GE
HealthCare, Piscataway, NJ) and 50 mM Tris-HCl buffer,
pH 7.5, supplemented with 250 mM NaCl. For determining the
protein oligomeric state, an analytic 10/300 Superdex 200 column
was used, with an elution flow rate of 0.5 mL per min. The
proteins were pre-incubated with FMN (1 mM, 2 h). They were
quantified using Pierce BCA (Thermo Fischer Scientific, Wal-
tham, MA) and Uptima (Interchim, Montluc ¸on, France) kits, using
bovine serum albumin as standard.
Site-directed mutagenesis was performed as described previous-
ly [7,15], using appropriate primers (Table S1). These were
designed to create single-codon mutations following the method of
Kuipers et al [16]. The wild type chrR gene cloned into expression
vector pET28a (Novagen, Emd Biochemicals, Gibbstown, NJ) was
used as mutagenesis template. Verification that the desired
mutations had been generated was obtained by sequencing.
Proteins encoded by the modified genes were generated as
described above. Chromate reductase activity was determined by
measuring decrease in chromate concentration during enzyme
assays, using the 1,5-diphenylcarbazide method as we have
described previously [17]. The enzyme was assayed at 37uCi n
0.3 mL reaction mixtures containing (final concentrations): Tris-
HCl buffer (50 mM, pH 7), chromate (1 mM), NADH (4 mM)
and 0.6 to 25 mg/L enzyme, depending on the samples. Two to
three protein concentrations were used for each determination.
For crystal structure determination, the untagged wild type
(WT) ChrR protein was concentrated to 26 mg/mL in Tris-HCl,
NaCl (10 and 150 mM, respectively, pH 8.0), and crystallized by
sitting drop vapor diffusion method, using PEG8000 (10%),
sodium chloride (50 mM) and calcium acetate (100 mM) solution
as precipitant. Hexagonal shaped crystals appeared after a day and
grew to about 0.1560.460.05 mm
3 in three weeks. X-ray
diffraction data of the native crystals were collected at a resolution
of 2.2 A ˚ at the X12C beamline of the National Synchrotron Light
Source (Brookhaven National Laboratory, Upton, NY). Highly
redundant data were collected by recording 360 images with 1u
rotation of the crystal and processed using the HKL2000 suite
[18]. The native crystals belonged to the hexagonal space group
P6322. The structure was solved by molecular replacement
method (MR).
Results
The MR method used to solve the ChrR crystal structure
employed the putative NADPH-dependent FMN-reductase T1501
of Pseudomonas aeruginosa PA01 [19] as model. Data collection details
and refinement statistics are given in Table 1. The MR solution had
a correlation coefficient of 0.302 between the two enzymes(R-factor
0.547) with two molecules in the asymmetric unit. This structure
was modified with ChrR amino acid sequence and refined to a final
R-factor of 0.404 (R-free 0.478). The phase values were calculated
using this structure and a new model was built with ARP_wARP [20]
through free atom calculations. The resulting model was checked
and correctedmanually using Program O [21] and refinedwithCNS
Table 1. Data collection and refinement statistics.
X-ray diffraction data
Unit Cell a: 107.25 A ˚
b: 107.25 A ˚
c: 128.25 A ˚
a:9 0 . 0 u
b:9 0 . 0 u
c:1 2 0 . 0 u
Space group: P6322
Resolution: 2.2 A ˚
Number of unique reflections: 22919
Completeness: 99.9%
R-merge
1: 0.155
I/sig(I): 7.7
Redundancy: 24.5
Structure refinement
R-work
2: 0.240
R-free: 0.273
Number of reflections R-work: 19964
R-free: 807
Number of atoms refined Protein: 2745
Co-factor: 62
Ion: 1
Water molecules: 84
Overall B-value: 17.9 A ˚2
Root mean square deviations Bond length: 0.007 A ˚
Bond angle: 1.3u
1Rsym=ShSi|Ii(h)2,I(h).|/ShSi |Ii(h)|, where Ii(h) is the intensity measurement
for a reflection h and ,I(h). is the mean intensity for this reflection.
2R-value=SiIFi,obs|2k|Fi,calI/Si|Fi,obs|.
doi:10.1371/journal.pone.0036017.t001
ChrR Structure
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showed an initial R-factor of 0.302 (R-free 0.332). A difference
electron-density map |Fo – Fc| (Fig. S1) calculated at 3.0s using
the completed protein structure showed an electron density
compatible with FMN prosthetic group, which was included in
the structure and further refined with water molecules (87 total).
The same residual density was also observed in the composite omit
map (not shown). Each monomer showed well-defined electron
density for the protein and the FMN. The crystal structure
(encompassing residues 4–184 in chain A and 4–185 in chain B)
shows a flavodoxin fold (Fig. 1A), with a central b-sheet made up of
five parallel b-strands in the order of b2, b1, b3, b4 and b5, and
surrounded by helices a1 and a5 on one side, and a2t oa4 on the
other. Loop 2 and loop 5 are long and more flexible than the other
loops.
FMN, representing the enzyme active site (Fig. 1A, B), is located
in a shallow cavity surrounded by loops 1, 3 and 4 at the C-
terminus of the b-sheet. FMN is anchored by several hydrogen
bonds to a typical strand-loop-helix nucleotide-binding motif
GSLRKGSFN (residues 12 to 20) located on loop 1 of the protein.
The three FMN phosphate oxygen atoms are strongly attached to
the protein. NH2 and NE groups of Arg15 form hydrogen bonds
with phosphate atoms O1 and O3. These phosphate groups have
additional interactions: O1 hydrogen bonds with N of Phe19, and
O3 contacts OG of Ser13 directly, and OH of Tyr83 through a
water molecule. Phosphate atom O2 binds within a 3.2 A ˚ distance
with OG of Ser18, and N and ND2 of Asn20. The flavin moiety
also has multiple interactions: O2 hydrogen bonds with OG of
Ser117; O4 with backbone nitrogens of Asn84 and Tyr85; and N3
with OE2 of Glu82. Moreover, Ser117 hydrogen bonds with O2
of ribitol, and the entire FMN molecule leans on loop 3 through
van der Walls interactions.
The asymmetric unit is composed of two molecules forming a
homo-dimer with a buried surface of 4670 A ˚ 2 (about 32%) for a
Figure 1. Crystal structure of ChrR. A: ChrR monomer; B: ChrR FMN-binding site; and C: ChrR tetramer. Underlined residues in panel B indicate
NAD(P)H-dependent FMN-reductase signature sequence. Side chain atoms of F19 have been removed for clarity. The residue R100 belongs to the
symmetry related molecule. Abbreviations: E=Glu; F=Phe; G=Gly; N=Asn; R=Arg; S=Ser; Y=Tyr; Wat=Water molecule.
doi:10.1371/journal.pone.0036017.g001
ChrR Structure
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between the two monomers are listed in Table S2. In the dimer, the
two FMN prosthetic groups locate at opposite sides of the interface
with loop 2 from one monomer covering the prosthetic group of the
other monomer. A potential metal binding site is observed in the
dimer interface, involving residues Asn50 and Asp52 (loop 2) from
one monomer and the carbonyl oxygen of Leu14 (loop 3) of the
other. A calcium ion has been modeled at this site because the
crystallization buffer contains calcium (Fig. S2).
The oligomeric structure of the ChrR enzyme in the crystal is a
tetramer, formed by two symmetry related dimers, as shown in
Fig. 1C, with a buried surface area of 48% (12550 A ˚ 2, for a total
tetramer surface area of 26050 A ˚ 2). It was possible that the
tetramer seen in the crystals resulted from the high concentration
of the protein used in making the crystals. However, size-exclusion
chromatography at various protein concentrations, including those
used for measuring the enzyme activity, showed that the active
enzyme is indeed a tetramer (Fig. 2). Within the tetramer, the
dimers interact by a pair of two hydrogen bond networks, each
involving Tyr128 and Glu146 of one dimer and Arg125 and
Tyr85 of the other with the latter extending to one of the redox
FMN cofactors, as shown in Fig. 3. Bond distances are given in
Table S3.
That Tyr128 is part of this network, and is closer to the FMN of
the other dimer (8.4 A ˚) than the FMN of its own dimer (14.1 A ˚),
was particularly notable to us because previous work from this lab
has shown that substitution of this residue by Asn (mutant enzyme
ChrR21) greatly improves chromate reductase activity of ChrR
[7]. Size exclusion chromatography, as done with the wild type
enzyme, showed that the active form of ChrR21 is also a tetramer
(Fig. 2). We wondered what effect changes of other three
individual amino acids in this network would have on chromate
reductase activity. Given that Asn is less bulky than Tyr, we chose
for these substitutions less bulky amino acids. Three additional
mutants ChrR41 (Glu146Thr), ChrR42 (Tyr85Asn), and ChrR43
(Arg125Met) were thus generated by site directed mutagenesis. All
were active as tetramers, as determined by the above method
(Fig. 2), and all showed improved chromate reductase activity
compared to the wild type enzyme (Table 2).
Figure 2. Oligomeric state of native ChrR and the mutants listed in Table 2 as determined by gel-filtration chromatography
(Superdex 200 10/300). Panel A shows absorbance at 280 nm as a function of the elution volume, and Panel B is the calibration curve. The active
enzymes are essentially tetrameric (peak b), as the dimer fraction (peak c) and protein aggregates (peak a) are negligible.
doi:10.1371/journal.pone.0036017.g002
Figure 3. Hydrogen bonding network between FMN molecules
from two different dimers of ChrR. Residue Tyr128 is closer to the
FMN belonging to the symmetry-related dimer (8.4 A ˚) than to the FMN
of the original molecule (14.1 A ˚). Abbreviations: E=Glu; R=Arg; Y=Tyr.
doi:10.1371/journal.pone.0036017.g003
ChrR Structure
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The wild type ChrR crystallized as a tetramer; size exclusion
chromatography under conditions used to measure chromate
reductase activity revealed this oligomeric form for the active
enzyme as well as the mutants listed in Table 2; and manipulation
of the amino acid constituents at the dimer-dimer interface
markedly improved the ChrR chromate reductase activity. Taken
collectively, these findings point to a central role for the tetrameric
configuration in chromate reductase activity of this enzyme.
Tetrameric association may be essential for the activity of small
flavoproteins like ChrR to accommodate their substrates.
Any definitive conclusions as to why the mutants shown in
Table 2 were improved in chromate reductase activity must await
co-crystallization of the wild type and the mutant enzymes with
chromate and NADH. It is, however, useful for future studies to
Table 2. Chromate reductase activity of ChrR mutant enzymes.
Enzyme nM Cr(VI) reduced/min/mg protein Enhancement factor
ChrR WT 860 (650)
ChrR 21 - Tyr128Asn 18065 (61123)* 621
ChrR 41 - Glu146Thr 25014 (61007) 629
ChrR 42 - Tyr85Asn 11496 (6134) 613
ChrR 43 - Arg125Met 8093 (6951) 69,4
*ChrR21 activity has been previously reported [7]. It was re-determined since.
protein preparation procedure and reaction mixtures used in this study are different from those used previously.
doi:10.1371/journal.pone.0036017.t002
Figure 4. Diagramatic representation of the possible ways by which Tyr128Asn substitution in ChrR may increase chromate
reductase activity. Fig. 4a and 4b show changes in hydrogen bonding between the dimers, and the surface diagrams (4c and 4d) show changes in
the cavity around FMN. Both diagrams show the same location but for clarity the surface diagram view is rotated 90u on Z-axis and 45u on X-axis of
the bonding diagram; Arg125 location is maintained at the top for direct comparison of the two views. See text for details.
doi:10.1371/journal.pone.0036017.g004
ChrR Structure
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improvement. The substitution of Tyr128 by Asn (ChrR21) is
likely to have the following two effects. First, whereas in the wild
type enzyme, three of the four hydrogen bonds between the dimers
converge on a single oxygen atom of Tyr128 (Fig. 4a), Asn
substitution would result in replacing them by individual bonds
between separate appropriate donor and acceptor atoms
[NE(R125)-H
…ND2(Asn128), NH1(Arg125)-H
…OD1(Asn128)
and NH1(R125)-H
…OE2(Glu146)] (Fig. 4b). Coupled with the
fact that Asn is less bulky, the result is likely to be greater stability
of the tetramer. A second potential effect concerns the cavity
surrounding FMN. While in the native enzyme the Arg125 side
chain reaches the solvent and restricts this cavity (Fig. 4c), the
smaller size of Asn compared to Tyr would make the Arg side
chain to turn inward to reach it, resulting in enlarged cavity
surrounding FMN and enhancing FMN accessibility (Fig. 4d).
Similar effects may contribute to the improved activity of the other
mutant enzymes, in which also an original bulkier amino acid was
replaced by a smaller one. Thus, in ChrR41, replacement of
Glu146 by Thr would confer freedom of movement on the side
chains of Tyr85 and Ty128, causing the side chain of Arg125 to
move towards the other dimer, which would likely make the
tetramer more stable and increase the accessible area of FMN.
And in ChrR43, the smaller side chain of Met compared to Arg
would enlarge the FMN cavity as in ChrR21 (Fig. 4d).
Additional factors are also likely to be involved. Tyr128 in the
native enzyme is in indirect hydrogen bonding interaction with the
FMN isoalloxazine N3H group, through Glu82 and Arg125 side
chains in the wild type enzyme (Fig. 3). Its substitution by the
shorter chain Asn may alter the hydrogen bonding interactions
involving the side chain of Glu82, affecting in turn its interaction
with ring III N3H group of FMN. The resulting change in the
properties of FMN could therefore also have a role in modifying
chromate reductase activity. Similarly, substitution of Arg125 by
Met in ChrR43 can be expected to perturb Glu82 properties and
hence properties of the FMN ring III.
Regardless, the results presented here indicate a critical role for
the hydrogen bond network involving the four amino acids at the
tetramer interface (Tyr128, Glu46, Arg125, Tyr85) in chromate
reductase activity of ChrR. We have shown that ChrR21 retains
its property for chromate reduction without Cr(V) formation [7]; it
is likely that the other mutants of Table 2 also retain this character.
Structurally, ChrR belongs to the FMN reductase family of
flavodoxin superfamily. Given its physiological role, it is part of the
quinone reductase enzymes sharing the flavodoxin-like fold
[23,24]. This role is to catalyze quinone reduction by simultaneous
two-electron transfer (avoiding formation of the reactive semiqui-
none intermediate), preempt reduction of diverse electrophiles
(e.g., quinones and chromate) by the cellular one-electron reducers
and generation of quinols that promote tolerance to ROS [9,14].
It thus constitutes, like the E. coli WrbA protein, a bridge between
bacterial and eukaryotic NAD(P)H:quinone oxidoreductases [23].
A search for protein data bases showed that ChrR bears the
closest structural similarity to the putative FMN-reductase of P.
aeruginosa PA01 T1501 (PDB ID: 1RTT) [19] (root mean square
deviation, 1.1 A ˚ for 174 atoms; 46% amino acid identity) – the
protein used to solve ChrR structure, as noted. In the tetrameric
form, T1501 also resembles ChrR in hydrogen bonding
interactions at the dimer-dimer interface. Other tetrameric
flavoproteins, such as ArsH or the quinone reductase YhdA,
while bearing less than 25% sequence similarity with ChrR, also
structurally resemble it (Z scores, 22.2 and 21.9, respectively).
However, their intermolecular interactions are different. In ChrR,
as stated, the dimer-dimer interaction involves a network of
hydrogen bonds involving FMN, Glu82, Tyr85 and Arg125 of one
dimer, and Tyr128 and Glu146 of the second dimer (Fig. 3). In
contrast, the dimer-dimer interaction in YhdA and ArsH involves
salt bridges between Lys109 and Asp137 [25], and extra loops
from N- and C- terminal extensions, respectively [24,26]. Whether
these differences affect the substrate range of these enzymes
remains to be determined.
One of our applied goals in the work on ChrR has been to
generate engineered bacteria for superior bioremediation includ-
ing their use at contaminated sites. Currently, there is reluctance
to introducing engineered bacteria into the environment. As this
may change, further improvement in bacterial capacity for in situ
bioremediation by molecular engineering remains a worthwhile
approach. In the meantime, however, the results reported here
could already lead to improved in situ bioremediation for the
following reason. We have seen that changes in four different
amino acids individually caused a significant increase in chromate
reductase activity and have shown that at least one of them
(ChrR21) [7] retains the capacity for ‘safe’ chromate reduction,
i.e., without Cr(V) generation. This suggests a strong possibility
that bacteria containing such mutant enzymes may have naturally
evolved in chromate contaminated sites to escape its toxicity.
Isolation of such bacteria from the polluted sites and their use in
bioaugmentation of these sites can thus be a promising approach
to improve chromate bioremediation [27,28,29].
The atomic coordinates and structure factors (code 3SVL) have
been deposited in the Protein Data Bank, Research Collaboratory
for Structural Bioinformatics, Rutgers.
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